Short answer
Xencor Inc (XNCR) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). Genentech terminating collaboration agreement with Xencor effective September 4, 2026: "for convenience" clause invoked.
Xencor Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Genentech terminating collaboration agreement with Xencor effective September 4, 2026: "for convenience" clause invoked
- Sole active drug (efbalropendekin alfa, engineered cytokine-Fc fusion) already cut from Roche's pipeline in January 2025: termination largely expected
- Xencor had already opted out of co-development cost-sharing in H1 2024, limiting further financial exposure from this program
- Loss of agreement removes any remaining milestone, royalty, or revenue potential tied to efbalropendekin alfa
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xencor Inc 8-K filings
Get the next XNCR 8-K as it lands
Follow XNCR for push alerts, or ask the research agent what this filing means.